Sofia Pappa
Overview
Explore the profile of Sofia Pappa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
2209
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fagiolini A, Leopold K, Pappa S, Cottam W, Hickey J, Rogerson O, et al.
Adv Ther
. 2025 Mar;
PMID: 40025389
Introduction: Aripiprazole once-monthly 400 mg (AOM 400) is a long-acting injectable (LAI) for the maintenance treatment of adults with schizophrenia. The AOM 400 two-injection start initiation regimen (AOM 400-TIS) is...
2.
Onwordi E, Whitehurst T, Shatalina E, Carr R, Mansur A, Arumuham A, et al.
Transl Psychiatry
. 2025 Mar;
15(1):70.
PMID: 40025026
Loss of glutamatergic terminals is hypothesised to contribute to excitation-inhibition imbalance in schizophrenia, supported by evidence that the normal positive association between glutamate concentrations and synaptic terminal density is not...
3.
Pappa S, Emsley R
Ther Adv Psychopharmacol
. 2024 Dec;
14:20451253241305610.
PMID: 39691770
No abstract available.
4.
Pappa S, Shah M, Young S, Anwar T, Ming T
J Psychiatr Res
. 2024 Nov;
180:511-518.
PMID: 39550927
Major depressive disorder (MDD), and particularly treatment-resistant depression (TRD), lead to high levels of health-care use and disease burden. The aim of this study was to evaluate and compare the...
5.
Kalniunas A, James K, Pappa S
BMJ Ment Health
. 2024 Sep;
27(1).
PMID: 39313255
Background: The aim of this systematic review and meta-analysis is to evaluate and compare the prevalence rates of spontaneous movement disorders (SMDs), including dyskinesia, parkinsonism, akathisia and dystonia, in antipsychotic-naïve...
6.
Pappa S, Caldwell-Dunn E, Kalniunas A, Kamal M
Front Psychiatry
. 2024 Aug;
15:1421698.
PMID: 39132320
Background: Emotionally unstable personality disorder (EUPD) is debilitating psychiatric disorder, particularly common in female and forensic populations. However, appropriate pharmacological treatment to effectively manage symptoms of EUPD remains an unmet...
7.
Asimakos A, Spetsioti S, Mentzelopoulos S, Vogiatzis I, Vassiliou A, Gounopoulos P, et al.
Respir Care
. 2024 Jul;
69(11):1361-1370.
PMID: 39043423
Background: Post-COVID-19 syndrome has affected millions of people, with rehabilitation being at the center of non-pharmacologic care. However, numerous published studies show conflicting results due to, among other factors, considerable...
8.
Pappa S, Shah M, Young S, Anwar T, Ming T
BJPsych Open
. 2024 Jan;
10(1):e32.
PMID: 38240079
Background: Despite the availability of effective therapies, many patients with major depressive disorder (MDD) develop treatment-resistant depression (TRD). Aims: To evaluate and compare prescribing patterns, contact with specialist services and...
9.
Garcia-Carmona J, Garcia-Perez A, Isidro Garcia G, Forcen-Munoz L, Ovejero Garcia S, Saez Povedano R, et al.
Ther Adv Psychopharmacol
. 2023 Dec;
13:20451253231220907.
PMID: 38152569
Background: Paliperidone palmitate 6-monthly (PP6M) is the first long-acting antipsychotic injectable (LAI) to allow for only two medication administrations per year, though there is presently limited insight into its effectiveness...
10.
Garcia-Carmona J, Pappa S
Drug Healthc Patient Saf
. 2023 Sep;
15:113-123.
PMID: 37720806
Paliperidone palmitate 3-monthly (PP3M), an approved maintenance treatment for patients with schizophrenia, was the first long-acting antipsychotic injectable (LAI) to require only four administrations per year. Here, we aimed to...